Novavax reported $22.1M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Adma Biologics USD 50.4M 8.24M Dec/2025
Agenus USD 642K 399K Sep/2025
AstraZeneca USD -204M 3.48B Mar/2026
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Cassava Sciences USD 3.96M 1.16M Sep/2025
Geron USD 1.69M 386K Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
MannKind USD 39.58M 5.94M Mar/2026
Merck USD 2.94B 380M Mar/2026
Minerva Neurosciences 386K 31K Jun/2024
Moderna USD 955M 503M Mar/2026
Novartis USD 3.54B 7M Dec/2025
Novavax USD 22.1M 608K Dec/2025
Pfizer USD 4.59B 1.7B Mar/2026
Sanofi EUR 3.67B 621M Mar/2026
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
TG Therapeutics USD 33.51M 4.63M Mar/2026